FDA Approves Pimozide Application ANDA219897 from Novitium Pharma
The FDA has approved the application ANDA219897 for Pimozide submitted by Novitium Pharma.
Published: July 26, 2026
Updated: July 26, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antipsychotic
Company: Novitium Pharma
Asset: Pimozide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Novitium Pharma
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Novitium Pharma's Pimozide application signifies increased competition in the antipsychotic market. This could impact pricing strategies and market share for existing products, necessitating a strategic response from other players in the sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Novitium's market launch timeline and initial sales performance of Pimozide.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.